First Patient Dosed in Phase II Renal Cancer Theranostics Study
Go back to First Patient Dosed in Phase II Renal Cancer Theranostics Study| TRANS-LUX CORPORATION (NASDAQ: TLX) | Delayed: 9.44 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.44 | 52 Week High | $2.18 | |||
| Open | $9.42 | 52 Week Low | $0.30 | |||
| Day High | $9.55 | P/E | N/A | |||
| Day Low | $9.34 | EPS | $-3.32 | |||
| Volume | 151,318 | |||||
